Anyone considering $TYME after the ER pullback? They have cash and cash equivalents of $31.5 million as of 1/7/20 with a cash burn rate between 5-6M per Q Upcoming catalysts for the first half of 2020 are: 1. preclinical data for SM-88 due 2. Advance enrollment in TYME-88-Panc pivotal study and the HopES Phase II Trial 3. Initiate enrollment in PanCAN’s Precision PromiseSM adaptive randomized Phase II/III registration 4. Preclinical data for TYME-18 due 5. Present preliminary Health Economic Outcomes study on total cost of care for pancreatic cancer patients 2nd half of 2020 is also looking promising with 5-6 catalysts
  • 4
  • 2